Tardive Dyskinesia (TD) is a movement disorder that is characterized by uncontrollable, abnormal, and repetitive movements of the face, torso, and/or other body parts, which may be disruptive and negatively impact patients. The condition is associated with prolonged use of treatments that block dopamine receptors in the brain, such as antipsychotics commonly prescribed to treat mental illnesses such as schizophrenia, bipolar disorder, and depression, and certain anti-nausea medications. In patients with TD, these treatments are thought to result in irregular dopamine signaling in a region of the brain that controls movement. The symptoms of TD can be severe and are often persistent and irreversible. It is estimated that at least 600,000 people in the United States are affected by Tardive Dyskinesia. Neurocrine Biosciences has a novel, oral treatment approved by the U.S. FDA, for the management of movement disorders associated with Tardive Dyskinesia.